We recently brought leading lab and diagnostics healthcare executives together in Washington, D.C., to discuss market opportunities and issues at HIDA’s first-ever Laboratory & Diagnostics Market Conference. It’s clear from several of our speakers and panel discussions that lab diagnostics are under-resourced and facing significant cost and reimbursement pressures as a result of the Affordable Care Act.
In my analysis of the ACA’s impact on lab markets (pdf) I explained how infections, for example, can cause health systems to be penalized under three different policies: readmissions, value-based purchasing, and infections penalties. However, these programs are creating new opportunities to elevate the role of diagnostics to be part of the solution for health systems to maximize reimbursement.
How are you using diagnostic testing to identify and prevent infections, preserving your company’s or customers’ lab reimbursement rates? Let us know in the comments below and look for other HIDA market conferences to address these issues in 2014.